Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
2020 · Cell Research · 877 citations
https://doi.org/10.1038/s41422-020-0356-z
J
Jun Wang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
359
Papers
14.5K
Citations
60
h-index
203
i10-index
Jun Wang is an academic researcher from Nankai University. The author has contributed to research in topics: Influenza Virus Research Studies & SARS-CoV-2 and COVID-19 Research & RNA and protein synthesis mechanisms. The author has an h-index of 60, co-authored 306 publications.
ORCID: 0000-0002-4845-4621Papers by this author
worksLipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations
2016 · Cell Host & Microbe · 392 citations
https://doi.org/10.1016/j.chom.2016.03.007
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
2021 · Nature Communications · 288 citations
https://doi.org/10.1038/s41467-021-26239-2
Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment
2014 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 234 citations
https://doi.org/10.1016/j.bbadis.2014.10.006
The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations
2022 · Medicinal Chemistry Research · 113 citations
https://doi.org/10.1007/s00044-022-02951-6
Enterovirus A71 antivirals: Past, present, and future
2021 · Acta Pharmaceutica Sinica B · 92 citations
https://doi.org/10.1016/j.apsb.2021.08.017
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat